LFCR — Lifecore Biomedical, Inc.

Summary of Lifecore Biomedical Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Revenues: $35.7 million, up 10% from $32.6 million in Q4 2024.
• 7-Month Transition Period Revenues: $75.5 million, a 20% increase from $63 million in the prior year.
• Gross Profit (Q4 2025): $12.8 million, compared to $11.1 million in Q4 2024; gross margin improved to 31%.
• Net Loss (Q4 2025): $5.1 million, or $0.16 per diluted share, improved from a loss of $6.6 million ($0.25 per share) in Q4 2024.
• Adjusted EBITDA (Q4 2025): $8.6 million, up from $6.5 million in Q4 2024; 7-month adjusted EBITDA was $13.1 million, significantly improved from $2.6 million in the prior year.
• Liquidity: Approximately $39 million, including $17.5 million in cash and $21 million available under a revolver.

2. Strategic Updates and Business Highlights:

• Lifecore is positioning for sustained growth with a target of 12% revenue CAGR and EBITDA margins above 25% in the midterm.
• Successful expansion of the commercial business, including qualification of a 5-head isolator filler for European and Asian markets.
• New high-value programs added to the late-stage pipeline, including two commercial site transfers expected to generate revenue in 24-30 months.
• Revamped business development strategy has led to five new programs, enhancing the quality and number of customer wins.
• Continued focus on operational efficiencies and cost control, with a significant reduction in SG&A expenses.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $120 million and $125 million.
• Net Loss Guidance for 2026: Projected between $28.9 million and $33.4 million.
• Adjusted EBITDA Guidance for 2026: Anticipated between $20.5 million and $25 million.
• Lifecore expects modest revenue growth in 2027, driven by existing customer programs and new commercial launches.

4. Bad News, Challenges, or Points of Concern:

• Anticipated loss of a customer due to a change in supply chain strategy, impacting revenue.
• Delays in a commercial launch due to customer funding challenges, pushing expected revenue contributions to 2028.
• Adjusted timelines for late-stage program launches from 2026-2029 to 2027-2030 due to external factors beyond Lifecore's control.
• The company faces risks related to customer concentration and the potential impact of financing market fluctuations.

5. Notable Q&A Insights:

• Lifecore's strategy for targeting Asian customers is primarily inbound, capitalizing on regionalization trends without aggressive outreach.
• Confidence in delayed commercial programs is bolstered by their existing success in other markets.
• The sales force restructuring is complete, with a focus on leveraging experienced leadership to drive future growth.
• Current fill/finish capacity is adequate for traditional vials but limited for prefilled syringes, which Lifecore aims to capitalize on.
• Expected free cash flow for 2026 is projected to exceed $10 million, with CapEx anticipated around $8 million.

Overall, Lifecore Biomedical reported strong financial performance in 2025, with strategic initiatives positioning the company for future growth despite facing some challenges and delays in customer programs.